RecruitingNCT07686263
Official study titleA Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants With Schizophrenia
Multiple locations, including BentonvilleSchizophreniaMedication studyAges 18–65
- Countries
- United States, Argentina, Bulgaria, + 4 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
RecruitingNCT07003529
Official study titleRôle Des Colliculi inférieurs Dans Les Hallucinations Auditives : étude Pilote Par Neuroimagerie
In NîmesSchizophreniaInterventional studyAges 18–60
- Countries
- France
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
RecruitingNCT06802939
In ShanghaiSchizophreniaDevice studyAges 13–55
- Countries
- China
- Sponsor
- Shanghai Mental Health Center
RecruitingNCT05648591
Official study titleOpen-label Safety Study of a 1-year 8 to 24 mg/Day Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder
Multiple locations, including DothanSchizophrenia, BipolarityMedication studyAges 12–17
- Countries
- United States
- Sponsor
- Vanda Pharmaceuticals
RecruitingNCT05440825
Official study titleSelf-management of Stress and Sleep Disturbances with Virtual Reality Relaxation for People with Burn-out, Mood, Anxiety or Psychotic Disorders: a Single-blind Randomized Controlled Trial
Multiple locations, including EnschedeSchizophreniaDevice studyAges 18+
- Countries
- Netherlands
- Sponsor
- University Medical Center Groningen
RecruitingNCT06839950
In LimogesPersonality disorders, SchizophreniaObservational studyAges 18–65
- Countries
- France
- Sponsor
- Centre Hospitalier Esquirol
RecruitingNCT01980147
Official study titleSkills for Wellness: Cognitive-behavioural Skills Training for Psychotic-like Experiences, Basic Symptoms, Affective Lability and Anxiety in Youth
In HalifaxSchizophrenia, Bipolarity, ...Behavioural studyAges 9–21
- Countries
- Canada
- Sponsor
- Nova Scotia Health Authority
RecruitingNCT07119268
Official study titleSPARK-Healthy Sleep: A Digital Health Intervention to Promote Behavioral, Emotional, and Cognitive Changes
In IndianapolisSchizophreniaDevice studyAges 18–65
- Countries
- United States
- Sponsor
- Indiana University
RecruitingNCT06831877
Official study titleTargeted Intervention Study of Deep Transcranial Magnetic Stimulation for Impaired Insight in Patients with High-Risk and First-Episode Psychosis
In ShanghaiSchizophreniaDevice studyAges 15–35
- Countries
- China
- Sponsor
- Shanghai Mental Health Center
RecruitingNCT07680946
What is this study about?Researchers are studying Ublituximab to find out how it affects psychotic symptoms in people with schizophrenia.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–60
- Countries
- United States
- Sponsor
- TG Therapeutics, Inc.
RecruitingNCT05500001
In EdmontonSchizophreniaBehavioural studyAges 17–27
- Countries
- Canada
- Sponsor
- University of Alberta
RecruitingNCT07121166
Official study titleEffectiveness of a Tele-group Cognitive Behavioural Family Intervention (tgCBFI) for People With Schizophrenia and Their Families: a Mixed-method Study
Multiple locations, including Chai WanSchizophreniaBehavioural studyAges 18–64
- Countries
- China
- Sponsor
- The Hong Kong Polytechnic University
Data coveragePublic registry coverage is progressing
HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.
Get research updates
